Rotolo Ornella, Bonfiglio Caterina, Reddavide Rosa, Cisternino Anna Maria, Inguaggiato Rosa, Giannelli Gianluigi
Clinical Trial Unit, National Institute of Gastroenterology IRCCS "Saverio de Bellis", Castellana Grotte, 70013 Bari, Italy.
Unit of Data Science, National Institute of Gastroenterology IRCCS "Saverio de Bellis", Castellana Grotte, 70013 Bari, Italy.
Nutrients. 2025 Sep 8;17(17):2905. doi: 10.3390/nu17172905.
Previous studies have shown a relationship between Visceral Adipose Tissue (VAT) and Hepatic Fat Content (HFC), and increases in HFC are linked to metabolic abnormalities similar to those associated with elevated VAT. Several short-term and long-term studies have supported these findings. Lifestyle interventions remain the cornerstone of treatment for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), although the ideal dietary regimen is still under debate.
Data on 2040 patients were extracted from the Clinical Nutrition Unit database between 2017 and 2019. Of these, 474 subjects with MASLD and Body Mass Index (BMI) ≥ 35 kg/m were treated with a four-month low-carbohydrate dietary intervention called the "Strong Diet" (StD). VAT and liver stiffness were measured at baseline and after four months of treatment using ultrasound.
Our study demonstrates the significant efficacy of StD in reducing VAT in MASLD patients with moderate hepatic steatosis. In subjects with severe steatosis, there is no statistically significant response to dietary intervention. This may be attributed to several irreversible molecular mechanisms that fundamentally alter the hepatic microenvironment and limit the liver's capacity for regeneration and metabolic recovery.
Improvements were largely confined to patients with moderate MASLD, with limited benefit in severe disease. Although dietary intervention remains the cornerstone of MASLD management, patients with severe steatosis should be informed about the potential limited resolution of steatosis, even with optimal metabolic control.
先前的研究表明内脏脂肪组织(VAT)与肝脂肪含量(HFC)之间存在关联,HFC的增加与代谢异常有关,这些异常类似于与VAT升高相关的代谢异常。多项短期和长期研究支持了这些发现。生活方式干预仍然是代谢功能障碍相关脂肪性肝病(MASLD)治疗的基石,尽管理想的饮食方案仍在讨论中。
从临床营养科数据库中提取了2017年至2019年期间2040例患者的数据。其中,474例患有MASLD且体重指数(BMI)≥35 kg/m²的受试者接受了为期四个月的名为“强化饮食”(StD)的低碳水化合物饮食干预。在基线和治疗四个月后,使用超声测量VAT和肝脏硬度。
我们的研究表明,StD在降低中度肝脂肪变性的MASLD患者的VAT方面具有显著疗效。在重度脂肪变性的受试者中,饮食干预没有统计学上的显著反应。这可能归因于几种不可逆的分子机制,这些机制从根本上改变了肝脏微环境,并限制了肝脏的再生和代谢恢复能力。
改善主要局限于中度MASLD患者,对重度疾病的益处有限。尽管饮食干预仍然是MASLD管理的基石,但应告知重度脂肪变性患者,即使进行最佳的代谢控制,脂肪变性的缓解可能也有限。